 I think oncology is gonna be, and cancer care in general, is gonna be at the forefront of the transformation of healthcare in general. The medicine is gonna, practice the medicine is gonna change more in the next 20 years and it'll change with 100 years. We have made a significant progress since the war on cancer in the early 70s with a dramatic drop in immortality at least by one third. On the other hand, there's still a lot of challenge in cancer with an increase of cancer incidence that is predicted as pro-American cancer society. 45% increase in the next 20, 25 years. There's still a lack of screening because early cancer always does better. 90, 95% of the patient who have a very early form of cancer will survive and that's very important. So what every patient wants is what's my best option? What's the best sequence of care? So that means have data analytics, precision medicine, immunotherapy and combined days to try to customize the treatment for the patient. Harnessing the immune system is not something new. This has been done 100 years ago where they were actually infecting tumors with bacteria to generate an immune response because they had noticed that actually it would make the tumor regress. The real leapfrog in immunotherapy came from a better understanding of immune response regulation and what dampens the immune response and by understanding on how the tumor plays with this and blocks the immune system and puts a break. We were able to design drugs that actually unleash the immune system and remove the break and that's called checkpoint inhibitors, one of the example. The other one is called Byte, which is by specific. It's an antibody structure, not really an antibody but a molecule that bridges the T cells and the tumor cells. CAR T cell is also a form of this. CAR T cell is making cells of the patient, manufacturing the receptor and putting the receptor in the cells to force the cells go after the cancer cells. All of this is to restore the normal ability of the immune system and to amplify this immune response to go after cancer. Why immunotherapy is very important, it's really critical because it shows response in patients who have failed all standard therapy. If you look at CAR T cell, in aggressive lymphoma, the median survival of patients who have failed the standard of combination of chemotherapy and every toxin map, for example, is in a few months at most. Now we can cure up to 40% of patients with CAR T cells. So we have patients that used to be sent to hospice that we can cure now with advanced disease and that's the power of immunotherapy because once you've reset the immune system, you don't have to continue to treat. The immune system takes care of it and that's what the beauty of it, so that's where I believe this is gonna be the foundational backbone of the future of cancer care.